← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Alopecia Areata

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented clinical diagnosis of Alopecia Areata (AA) for at least 6 months
Be older than 18 years old
Must not have
Participant with diffuse-type AA or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a medication called Deucravacitinib to see if it can help adults with Alopecia Areata, a condition where people lose hair in patches. The study will compare the effects of Deucravacitinib to another treatment over several months. The goal is to find out if the medication is effective and safe.

Who is the study for?
This trial is for adults with Alopecia Areata who've had the condition for at least 6 months, with current hair loss affecting over half their scalp and stable for the past 6 months. They should have a SALT score of at least 50, indicating significant hair loss. Those with other types of hair loss or skin conditions that could affect scalp assessment can't participate.
What is being tested?
The study is testing Deucravacitinib's effectiveness compared to a placebo in improving symptoms by Week 24. Participants will be randomly assigned to receive either Deucravacitinib or a placebo, allowing researchers to measure the drug's true impact on Alopecia Areata.
What are the potential side effects?
While specific side effects are not listed here, participants may experience adverse reactions related to Deucravacitinib which will be closely monitored against those taking the placebo for safety and tolerability.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Alopecia Areata for at least 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a type of hair loss such as diffuse AA or traction alopecia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Deucravacitinib Dose 2Experimental Treatment2 Interventions
Group II: Deucravacitinib Dose 1Experimental Treatment2 Interventions
Group III: Placebo, followed by Deucravacitinib Dose 1 or Dose 2.Placebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Alopecia Areata is primarily driven by an autoimmune response where cytotoxic T lymphocytes attack hair follicles. Treatments like Deucravacitinib, a selective TYK2 inhibitor, work by modulating the immune system to reduce this inflammatory response. Similar treatments include JAK inhibitors like tofacitinib and ruxolitinib, which also target pathways involved in immune signaling to prevent hair follicle destruction. Other common treatments, such as corticosteroids and immunosuppressants like methotrexate and cyclosporine, broadly suppress the immune system to reduce inflammation. Understanding these mechanisms is crucial for patients, as it helps them grasp how these treatments can potentially halt or reverse hair loss by addressing the underlying immune dysfunction.

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,679 Previous Clinical Trials
4,125,117 Total Patients Enrolled
1 Trials studying Alopecia Areata
15 Patients Enrolled for Alopecia Areata

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05556265 — Phase 2
Alopecia Areata Research Study Groups: Deucravacitinib Dose 1, Deucravacitinib Dose 2, Placebo, followed by Deucravacitinib Dose 1 or Dose 2.
Alopecia Areata Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT05556265 — Phase 2
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05556265 — Phase 2
Alopecia Areata Patient Testimony for trial: Trial Name: NCT05556265 — Phase 2
~33 spots leftby Oct 2025